Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

An Expert Overview of Immunotherapy for Advanced HCC
  • CME

Loading...
Listen to Amit G. Singal, MD, MS, and Lipika Goyal, MD, as they provide a succinct discussion of key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma.
Lipika Goyal, MD
Amit G. Singal, MD, MS
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: January 19, 2021 Expiration: January 18, 2022

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:

  • Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
  • Use of nivolumab ± ipilimumab and pembrolizumab
  • Emerging immunotherapy combinations currently being investigated in clinical trials
  • Management of key adverse events with immune checkpoint inhibitors

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients with HCC most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, comorbid liver diseases, and patient characteristics and preferences
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC, while also managing comorbid liver diseases

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Amit G. Singal, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exact Sciences, Exelixis, Genentech/Roche, Glycotest, GRAIL, Merck, and Wako.
Lipika Goyal, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Lipika Goyal, MD, has disclosed that she has received consulting fees from Agios, Alentis, AstraZeneca, Debiopharm, H3 Biomedicine, Incyte, QED Therapeutics, Sirtex, and Taiho.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hepatologists and other healthcare providers who care for patients with HCC.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners in their clinical use of optimal HCC immunotherapy options.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 19, 2021, through January 18, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastrointestinal cancer

Allison M. Cushman-Vokoun, MD, PhD John L. Marshall, MD Released: August 5, 2021

Video of a live Clinical Care Options (CCO) webinar on immune checkpoint inhibitors for HCC and other hepatobiliary cancers

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Expert review of key data in GI cancers from the 2021 ASCO annual meeting, from Clinical Care Options (CCO)

Manish A. Shah, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue